SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI), a pioneer in protein design and synthesis,
announced that it has applied for a listing on the American Stock Exchange
(the "Exchange" or "Amex").  The company's stock is currently traded on the
OTC Bulletin Board under the symbol PPTI.OB.
    "We are excited by the prospect of joining other emerging growth companies
listed on the American Stock Exchange," stated William N. Plamondon, III,
PPTI's Chief Executive Officer.  "The listing on the American Stock Exchange
should improve our company's visibility among investors while enhancing
trading liquidity for our shares."

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices.  These genetically engineered biomaterials
are high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements. Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery. To date, PPTI has been issued twenty-six U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up.  The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, and
other recent filings with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain the risks
associated with the above statements.

Link to this page: